The DOI matches its Crossref record; 134 of the 134 references it cites were found in a registry or an index.
The role of the ALK receptor in cancer biology
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer
Soda, M., Choi, Y. L., Enomoto, M., Takada, S., Yamashita, Y., Ishikawa, S., Fujiwara, S.-I., Watanabe, H., Kurashina, K., Hatanaka, H., et al. (2007) · Nature · doi:10.1038/nature05945 · Cited by 5,439
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
Kwak, E. L., Bang, Y.-J., Camidge, D. R., Shaw, A. T., Solomon, B., Maki, R. G., Ou, S.-H. I., Dezube, B. J., Jänne, P. A., Costa, D. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1006448 · Cited by 4,446
First-Line Crizotinib versus Chemotherapy in ALK -Positive Lung Cancer
Solomon, B. J., Mok, T., Kim, D.-W., Wu, Y.-L., Nakagawa, K., Mekhail, T., Felip, E., Cappuzzo, F., Paolini, J., Usari, T., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1408440 · Cited by 3,190
Fusion of a Kinase Gene, ALK , to a Nucleolar Protein Gene, NPM , in Non-Hodgkin's Lymphoma
Morris, S. W., Kirstein, M. N., Valentine, M. B., Dittmer, K. G., Shapiro, D. N., Saltman, D. L., & Look, A. T. (1994) · Science · doi:10.1126/science.8122112 · Cited by 2,409
Global Survey of Phosphotyrosine Signaling Identifies Oncogenic Kinases in Lung Cancer
Rikova, K., Guo, A., Zeng, Q., Possemato, A., Yu, J., Haack, H., Nardone, J., Lee, K., Reeves, C., Li, Y., et al. (2007) · Cell · doi:10.1016/j.cell.2007.11.025 · Cited by 2,317
Identification of ALK as a major familial neuroblastoma predisposition gene
Mossé, Y. P., Laudenslager, M., Longo, L., Cole, K. A., Wood, A., Attiyeh, E. F., Laquaglia, M. J., Sennett, R., Lynch, J. E., Perri, P., et al. (2008) · Nature · doi:10.1038/nature07261 · Cited by 1,407
Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers
Katayama, R., Shaw, A. T., Khan, T. M., Mino-Kenudson, M., Solomon, B. J., Halmos, B., Jessop, N. A., Wain, J. C., Yeo, A. T., Benes, C., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003316 · Cited by 1,309
EML4-ALK Mutations in Lung Cancer That Confer Resistance to ALK Inhibitors
Choi, Y. L., Soda, M., Yamashita, Y., Ueno, T., Takashima, J., Nakajima, T., Yatabe, Y., Takeuchi, K., Hamada, T., Haruta, H., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1007478 · Cited by 1,189
Jemal, A., Clegg, L. X., Ward, E., Ries, L. A. G., Wu, X., Jamison, P. M., Wingo, P. A., Howe, H. L., Anderson, R. N., & Edwards, B. K. (2004) · Cancer · doi:10.1002/cncr.20288 · Cited by 1,140
Immunoaffinity profiling of tyrosine phosphorylation in cancer cells
Rush, J., Moritz, A., Lee, K. A., Guo, A., Goss, V. L., Spek, E. J., Zhang, H., Zha, X.-M., Polakiewicz, R. D., & Comb, M. J. (2005) · Nature Biotechnology · doi:10.1038/nbt1046 · Cited by 1,124
Doebele, R. C., Pilling, A. B., Aisner, D. L., Kutateladze, T. G., Le, A. T., Weickhardt, A. J., Kondo, K. L., Linderman, D. J., Heasley, L. E., Franklin, W. A., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2906 · Cited by 1,063
Oncogenic mutations of ALK kinase in neuroblastoma
Chen, Y., Takita, J., Choi, Y. L., Kato, M., Ohira, M., Sanada, M., Wang, L., Soda, M., Kikuchi, A., Igarashi, T., et al. (2008) · Nature · doi:10.1038/nature07399 · Cited by 916
Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma
Janoueix-Lerosey, I., Lequin, D., Brugières, L., Ribeiro, A., de Pontual, L., Combaret, V., Raynal, V., Puisieux, A., Schleiermacher, G., Pierron, G., et al. (2008) · Nature · doi:10.1038/nature07398 · Cited by 894
Activating mutations in ALK provide a therapeutic target in neuroblastoma
George, R. E., Sanda, T., Hanna, M., Fröhling, S., II, W. L., Zhang, J., Ahn, Y., Zhou, W., London, W. B., McGrady, P., et al. (2008) · Nature · doi:10.1038/nature07397 · Cited by 893
Crizotinib in ALK-Rearranged Inflammatory Myofibroblastic Tumor
Butrynski, J. E., D'Adamo, D. R., Hornick, J. L., Dal Cin, P., Antonescu, C. R., Jhanwar, S. C., Ladanyi, M., Capelletti, M., Rodig, S. J., Ramaiya, N., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1007056 · Cited by 870
The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non–Small Cell Lung Cancer
Friboulet, L., Li, N., Katayama, R., Lee, C. C., Gainor, J. F., Crystal, A. S., Michellys, P.-Y., Awad, M. M., Yanagitani, N., Kim, S., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0846 · Cited by 840
Iwahara, T., Fujimoto, J., Wen, D., Cupples, R., Bucay, N., Arakawa, T., Mori, S., Ratzkin, B., & Yamamoto, T. (1997) · Oncogene · doi:10.1038/sj.onc.1200849 · Cited by 726
Takeuchi, K., Choi, Y. L., Togashi, Y., Soda, M., Hatano, S., Inamura, K., Takada, S., Ueno, T., Yamashita, Y., Satoh, Y., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-3248 · Cited by 717
Mossé, Y. P., Lim, M. S., Voss, S. D., Wilner, K., Ruffner, K., Laliberte, J., Rolland, D., Balis, F. M., Maris, J. M., Weigel, B. J., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70095-0 · Cited by 712
Christensen, J. G., Zou, H. Y., Arango, M. E., Li, Q., Lee, J. H., McDonnell, S. R., Yamazaki, S., Alton, G. R., Mroczkowski, B., & Los, G. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-0365 · Cited by 649
Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology
Hallberg, B., & Palmer, R. H. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3580 · Cited by 645
Self-citationCH5424802, a Selective ALK Inhibitor Capable of Blocking the Resistant Gatekeeper Mutant
Sakamoto, H., Tsukaguchi, T., Hiroshima, S., Kodama, T., Kobayashi, T., Fukami, T. A., Oikawa, N., Tsukuda, T., Ishii, N., & Aoki, Y. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.04.004 · Cited by 636
Johnson, T. W., Richardson, P. F., Bailey, S., Brooun, A., Burke, B. J., Collins, M. R., Cui, J. J., Deal, J. G., Deng, Y.-L., Dinh, D., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm500261q · Cited by 594
The biology and treatment of EML4-ALK non-small cell lung cancer
Sasaki, T., Rodig, S. J., Chirieac, L. R., & Jänne, P. A. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2010.04.002 · Cited by 555
Katayama, R., Khan, T. M., Benes, C., Lifshits, E., Ebi, H., Rivera, V. M., Shakespeare, W. C., Iafrate, A. J., Engelman, J. A., & Shaw, A. T. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1019559108 · Cited by 542
Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations
Eleveld, T. F., Oldridge, D. A., Bernard, V., Koster, J., Daage, L. C., Diskin, S. J., Schild, L., Bentahar, N. B., Bellini, A., Chicard, M., et al. (2015) · Nature Genetics · doi:10.1038/ng.3333 · Cited by 540
Morris, S. W., Naeve, C., Mathew, P., James, P. L., Kirstein, M. N., Cui, X., & Witte, D. P. (1997) · Oncogene · doi:10.1038/sj.onc.1201062 · Cited by 524
A mouse model for EML4-ALK -positive lung cancer
Soda, M., Takada, S., Takeuchi, K., Choi, Y. L., Enomoto, M., Ueno, T., Haruta, H., Hamada, T., Yamashita, Y., Ishikawa, Y., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0805381105 · Cited by 512
Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F
Shaw, A. T., Friboulet, L., Leshchiner, I., Gainor, J. F., Bergqvist, S., Brooun, A., Burke, B. J., Deng, Y.-L., Liu, W., Dardaei, L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1508887 · Cited by 484
ALK in Lung Cancer: Past, Present, and Future
Shaw, A. T., & Engelman, J. A. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.5353 · Cited by 461
Marsilje, T. H., Pei, W., Chen, B., Lu, W., Uno, T., Jin, Y., Jiang, T., Kim, S., Li, N., Warmuth, M., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400402q · Cited by 418
Bresler, S. C., Weiser, D. A., Huwe, P. J., Park, J. H., Krytska, K., Ryles, H., Laudenslager, M., Rappaport, E. F., Wood, A. C., McGrady, P. W., et al. (2014) · Cancer Cell · doi:10.1016/j.ccell.2014.09.019 · Cited by 388
Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK
Galkin, A. V., Melnick, J. S., Kim, S., Hood, T. L., Li, N., Li, L., Xia, G., Steensma, R., Chopiuk, G., Jiang, J., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0609412103 · Cited by 379
Activated ALK Collaborates with MYCN in Neuroblastoma Pathogenesis
Zhu, S., Lee, J.-S., Guo, F., Shin, J., Perez-Atayde, A. R., Kutok, J. L., Rodig, S. J., Neuberg, D. S., Helman, D., Feng, H., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.02.010 · Cited by 365
Emerging Paradigms in the Development of Resistance to Tyrosine Kinase Inhibitors in Lung Cancer
Gainor, J. F., & Shaw, A. T. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.2029 · Cited by 346
The ALKF1174L Mutation Potentiates the Oncogenic Activity of MYCN in Neuroblastoma
Berry, T., Luther, W., Bhatnagar, N., Jamin, Y., Poon, E., Sanda, T., Pei, D., Sharma, B., Vetharoy, W. R., Hallsworth, A., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.06.001 · Cited by 326
Self-citationBai, R.-Y., Ouyang, T., Miething, C., Morris, S. W., Peschel, C., & Duyster, J. (2000) · Blood · doi:10.1182/blood.v96.13.4319 · Cited by 319
Two Novel ALK Mutations Mediate Acquired Resistance to the Next-Generation ALK Inhibitor Alectinib
Katayama, R., Friboulet, L., Koike, S., Lockerman, E. L., Khan, T. M., Gainor, J. F., Iafrate, A. J., Takeuchi, K., Taiji, M., Okuno, Y., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1511 · Cited by 290
Dynamics-Driven Allostery in Protein Kinases
Kornev, A. P., & Taylor, S. S. (2015) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2015.09.002 · Cited by 284
Bai, R.-Y., Dieter, P., Peschel, C., Morris, S. W., & Duyster, J. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.12.6951 · Cited by 281
Carén, H., Abel, F., Kogner, P., & Martinsson, T. (2008) · Biochemical Journal · doi:10.1042/bj20081834 · Cited by 280
Togashi, Y., Soda, M., Sakata, S., Sugawara, E., Hatano, S., Asaka, R., Nakajima, T., Mano, H., & Takeuchi, K. (2012) · PLoS ONE · doi:10.1371/journal.pone.0031323 · Cited by 267
Defining the conserved internal architecture of a protein kinase
Kornev, A. P., & Taylor, S. S. (2010) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2009.10.017 · Cited by 266
Katayama, R., Lovly, C. M., & Shaw, A. T. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2791 · Cited by 257
Anaplastic Lymphoma Kinase Spares Organ Growth during Nutrient Restriction in Drosophila
Cheng, L. Y., Bailey, A. P., Leevers, S. J., Ragan, T. J., Driscoll, P. C., & Gould, A. P. (2011) · Cell · doi:10.1016/j.cell.2011.06.040 · Cited by 252
NPM-ALK transgenic mice spontaneously develop T-cell lymphomas and plasma cell tumors
Chiarle, R., Gong, J. Z., Guasparri, I., Pesci, A., Cai, J., Liu, J., Simmons, W. J., Dhall, G., Howes, J., Piva, R., et al. (2003) · Blood · doi:10.1182/blood-2002-05-1343 · Cited by 252
Shiota, M., Fujimoto, J., Semba, T., Satoh, H., Yamamoto, T. S., & Mori, S. (1994) · PubMed · Cited by 246
Differential Inhibitor Sensitivity of Anaplastic Lymphoma Kinase Variants Found in Neuroblastoma
Bresler, S. C., Wood, A. C., Haglund, E. A., Courtright, J., Belcastro, L. T., Plegaria, J. S., Cole, K., Toporovskaya, Y., Zhao, H., Carpenter, E. L., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002950 · Cited by 237
An SCF-like ubiquitin ligase complex that controls presynaptic differentiation
Liao, E. H., Hung, W., Abrams, B., & Zhen, M. (2004) · Nature · doi:10.1038/nature02647 · Cited by 233
Emergence of New ALK Mutations at Relapse of Neuroblastoma
Schleiermacher, G., Javanmardi, N., Bernard, V., Leroy, Q., Cappo, J., Rio Frio, T., Pierron, G., Lapouble, E., Combaret, V., Speleman, F., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.0674 · Cited by 215
Chia, P. L., John, T., Dobrovic, A., & Mitchell, P. (2014) · Clinical Epidemiology · doi:10.2147/clep.s69718 · Cited by 199
Jelly belly protein activates the receptor tyrosine kinase Alk to specify visceral muscle pioneers
Lee, H.-H., Norris, A., Weiss, J. B., & Frasch, M. (2003) · Nature · doi:10.1038/nature01916 · Cited by 194
Anaplastic Thyroid Cancers Harbor Novel Oncogenic Mutations of the ALK Gene
Murugan, A. K., & Xing, M. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-4041 · Cited by 193
ALK Mutations Conferring Differential Resistance to Structurally Diverse ALK Inhibitors
Heuckmann, J. M., Hölzel, M., Sos, M. L., Heynck, S., Balke-Want, H., Koker, M., Peifer, M., Weiss, J., Lovly, C. M., Grütter, C., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1648 · Cited by 191
Chen, Z., Sasaki, T., Tan, X., Carretero, J., Shimamura, T., Li, D., Xu, C., Wang, Y., Adelmant, G. O., Capelletti, M., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1671 · Cited by 191
Bilsland, J. G., Wheeldon, A., Mead, A., Znamenskiy, P., Almond, S., Waters, K. A., Thakur, M., Beaumont, V., Bonnert, T. P., Heavens, R., et al. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301446 · Cited by 188
Matsuyama, H., Suzuki, H. I., Nishimori, H., Noguchi, M., Yao, T., Komatsu, N., Mano, H., Sugimoto, K., & Miyazono, K. (2011) · Blood · doi:10.1182/blood-2011-05-354654 · Cited by 182
Ishihara, T., Iino, Y., Mohri, A., Mori, I., Gengyo-Ando, K., Mitani, S., & Katsura, I. (2002) · Cell · doi:10.1016/s0092-8674(02)00748-1 · Cited by 182
Crystal structure of the ALK (anaplastic lymphoma kinase) catalytic domain
Lee, C. C., Jia, Y., Li, N., Sun, X., Ng, K., Ambing, E., Gao, M.-Y., Hua, S., Chen, C., Kim, S., et al. (2010) · Biochemical Journal · doi:10.1042/bj20100609 · Cited by 182
Targeted Expression of Mutated ALK Induces Neuroblastoma in Transgenic Mice
Heukamp, L. C., Thor, T., Schramm, A., De Preter, K., Kumps, C., De Wilde, B., Odersky, A., Peifer, M., Lindner, S., Spruessel, A., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003967 · Cited by 181
Jeb signals through the Alk receptor tyrosine kinase to drive visceral muscle fusion
Englund, C., Lorén, C. E., Grabbe, C., Varshney, G. K., Deleuil, F., Hallberg, B., & Palmer, R. H. (2003) · Nature · doi:10.1038/nature01950 · Cited by 179
Self-citationGainor, J. F., Tan, D. S. W., De Pas, T., Solomon, B. J., Ahmad, A., Lazzari, C., de Marinis, F., Spitaleri, G., Schultz, K., Friboulet, L., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-3009 · Cited by 177
Crystal Structures of Anaplastic Lymphoma Kinase in Complex with ATP Competitive Inhibitors
Bossi, R. T., Saccardo, M. B., Ardini, E., Menichincheri, M., Rusconi, L., Magnaghi, P., Orsini, P., Avanzi, N., Borgia, A. L., Nesi, M., et al. (2010) · Biochemistry · doi:10.1021/bi1005514 · Cited by 173
Ou, S.-H. I., Azada, M., Hsiang, D. J., Herman, J. M., Kain, T. S., Siwak-Tapp, C., Casey, C., He, J., Ali, S. M., Klempner, S. J., et al. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000094 · Cited by 172
McTigue, M. A., Deng, Y. L., Liu, W., Brooun, A., & Stewart, A. E. (2014) · Worldwide Protein Data Bank · doi:10.2210/pdb4ctb/pdb · Cited by 170
Leukocyte Tyrosine Kinase Functions in Pigment Cell Development
Lopes, S. S., Yang, X., Müller, J., Carney, T. J., McAdow, A. R., Rauch, G.-J., Jacoby, A. S., Hurst, L. D., Delfino-Machín, M., Haffter, P., et al. (2008) · PLoS Genetics · doi:10.1371/journal.pgen.1000026 · Cited by 163
Piva, R., Pellegrino, E., Mattioli, M., Agnelli, L., Lombardi, L., Boccalatte, F., Costa, G., Ruggeri, B. A., Cheng, M., Chiarle, R., et al. (2006) · Journal of Clinical Investigation · doi:10.1172/jci29401 · Cited by 163
Bazigou, E., Apitz, H., Johansson, J., Lorén, C. E., Hirst, E. M. A., Chen, P.-L., Palmer, R. H., & Salecker, I. (2007) · Cell · doi:10.1016/j.cell.2007.02.024 · Cited by 161
Self-citationMoog-Lutz, C., Degoutin, J., Gouzi, J. Y., Frobert, Y., Carvalho, N. B.-D., Bureau, J., Créminon, C., & Vigny, M. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m501972200 · Cited by 158
FAM150A and FAM150B are activating ligands for anaplastic lymphoma kinase
Guan, J., Umapathy, G., Yamazaki, Y., Wolfstetter, G., Mendoza-García, P., Pfeifer, K., Mohammed, A., Hugosson, F., Zhang, H., Hsu, A. W., et al. (2015) · eLife · doi:10.7554/elife.09811 · Cited by 150
Self-citationReshetnyak, A. V., Murray, P. B., Shi, X., Mo, E. S., Mohanty, J., Tomé, F., Bai, H., Günel, M., Lax, I., & Schlessinger, J. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1520099112 · Cited by 150
Desjobert, C., Renalier, M.-H., Bergalet, J., Dejean, E., Joseph, N., Kruczynski, A., Soulier, J., Espinos, E., Meggetto, F., Cavaillé, J., et al. (2011) · Blood · doi:10.1182/blood-2010-09-301994 · Cited by 131
The anaplastic lymphoma kinase is an effective oncoantigen for lymphoma vaccination
Chiarle, R., Martinengo, C., Mastini, C., Ambrogio, C., d’Escamard, V., Forni, G., & Inghirami, G. (2008) · Nature Medicine · doi:10.1038/nm1769 · Cited by 129
Armstrong, F., Duplantier, M.-M., Trempat, P., Hiéblot, C., Lamant, L., Espinos, E., Racaud‐Sultan, C., Allouche, M., Campo, E., Delsol, G., et al. (2004) · Oncogene · doi:10.1038/sj.onc.1207813 · Cited by 129
Molecular mechanisms that underpin EML4-ALK driven cancers and their response to targeted drugs
Bayliss, R. W., Choi, J., Fennell, D. A., Fry, A. M., & Richards, M. W. (2016) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-015-2117-6 · Cited by 127
Lorén, C. E., Scully, A. L., Grabbe, C., Edeen, P. T., Thomas, J. B., McKeown, M., Hunter, T. R., & Palmer, R. H. (2001) · Genes to Cells · doi:10.1046/j.1365-2443.2001.00440.x · Cited by 123
Self-citationSchönherr, C., Ruuth, K., Kamaraj, S., Wang, C.-L., Yang, H.-L., Combaret, V., Djos, A., Martinsson, T., Christensen, J. G., Palmer, R. H., et al. (2012) · Oncogene · doi:10.1038/onc.2012.12 · Cited by 122
Self-citationIdentification of recurrent FGFR3 fusion genes in lung cancer through kinome‐centred RNA sequencing
Majewski, I. J., Mittempergher, L., Davidson, N., Bosma, A. R., Willems, S. M., Horlings, H. M., de Rink, I., Greger, L., Hooijer, G. K. J., Peters, D. D. G. C., et al. (2013) · The Journal of Pathology · doi:10.1002/path.4209 · Cited by 119
Weiss, J. B., Xue, C., Benice, T. S., Xue, L., Morris, S. W., & Raber, J. (2011) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2011.10.024 · Cited by 117
Staber, P. B., Vesely, P. W., Haq, N., Ott, R. G., Funato, K., Bambach, I., Fuchs, C. D., Schauer, S., Linkesch, W., Hrzenjak, A., et al. (2007) · Blood · doi:10.1182/blood-2007-02-071258 · Cited by 117
The Receptor Tyrosine Kinase Alk Controls Neurofibromin Functions in Drosophila Growth and Learning
Gouzi, J. Y., Moressis, A., Walker, J. A., Apostolopoulou, A. A., Palmer, R. H., Bernards, A., & Skoulakis, E. M. C. (2011) · PLoS Genetics · doi:10.1371/journal.pgen.1002281 · Cited by 113
Self-citationAn Evolutionary Conserved Role for Anaplastic Lymphoma Kinase in Behavioral Responses to Ethanol
Lasek, A. W., Lim, J. P., Kliethermes, C. L., Berger, K. H., Joslyn, G., Brush, G., Xue, L., Robertson, M. A., Moore, M. S., VRANIZAN, K. M., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0022636 · Cited by 112
Dejean, E., Renalier, M.-H., Foisseau, M., Agirre, X., Joseph, N., Silva, G. R. D. P., Saati, T. A., Soulier, J., Desjobert, C., Lamant, L., et al. (2011) · Leukemia · doi:10.1038/leu.2011.168 · Cited by 111
Crizotinib Synergizes with Chemotherapy in Preclinical Models of Neuroblastoma
Krytska, K., Ryles, H. T., Sano, R., Raman, P., Infarinato, N. R., Hansel, T. D., Makena, M. R., Song, M. M., Reynolds, C. P., & Mossé, Y. P. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0379 · Cited by 111
Cazes, A., Lopez‐Delisle, L., Tsarovina, K., Pierre‐Eugène, C., Preter, K. D., Peuchmaur, M. M., Nicolas, A., Provost, C., Louis‐Brennetot, C., Daveau, R., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.1883 · Cited by 108
Okamoto, N., & Nishimura, T. (2015) · Developmental Cell · doi:10.1016/j.devcel.2015.10.003 · Cited by 106
Voena, C., Conte, C., Ambrogio, C., Erba, E. B., Boccalatte, F. E., Mohammed, S., Jensen, O. N., Palestro, G., Inghirami, G., & Chiarle, R. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4350 · Cited by 103
Ou, S. I., Klempner, S. J., Greenbowe, J. R., Azada, M. C., Schrock, A. B., Ali, S. M., Ross, J. S., Stephens, P. J., & Miller, V. A. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000368 · Cited by 100
Moore, N. F., Azarova, A. M., Bhatnagar, N., Ross, K. N., Drake, L. E., Frumm, S. M., Liu, Q. S., Christie, A. L., Sanda, T., Chesler, L., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2372 · Cited by 96
Jung, Y., Kim, P., Jung, Y., Keum, J., Kim, S., Choi, Y. S., Do, I., Lee, J., Choi, S., Kim, S., et al. (2012) · Genes Chromosomes and Cancer · doi:10.1002/gcc.21945 · Cited by 95
HIP1–ALK, A Novel ALK Fusion Variant that Responds to Crizotinib
Fang, D. D., Zhang, B., Gu, Q., Lira, M. E., Xu, Q., Sun, H., Qian, M., Sheng, W., Ozeck, M., Wang, Z., et al. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000087 · Cited by 95
Umapathy, G., Wakil, A. E., Witek, B., Chesler, L., Danielson, L. S., Deng, X., Gray, N. S., Johansson, M., Kvarnbrink, S., Ruuth, K., et al. (2014) · Science Signaling · doi:10.1126/scisignal.2005470 · Cited by 95
Self-citationWeiss, J. B., Suyama, K. L., Lee, H., & Scott, M. P. (2001) · Cell · doi:10.1016/s0092-8674(01)00540-2 · Cited by 91
Activating ALK mutations found in neuroblastoma are inhibited by Crizotinib and NVP-TAE684
Schönherr, C., Ruuth, K., Yamazaki, Y., Eriksson, T., Christensen, J. G., Palmer, R. H., & Hallberg, B. (2011) · Biochemical Journal · doi:10.1042/bj20101796 · Cited by 87
Self-citationReiner, D. J., Ailion, M., Thomas, J. H., & Meyer, B. J. (2008) · Current Biology · doi:10.1016/j.cub.2008.06.060 · Cited by 86
NIPA Defines an SCF-Type Mammalian E3 Ligase that Regulates Mitotic Entry
Bassermann, F. C., von Klitzing, C., Münch, S., Bai, R.-Y., Kawaguchi, H., Morris, S. W., Peschel, C., & Duyster, J. (2005) · Cell · doi:10.1016/j.cell.2005.04.034 · Cited by 84
Tartari, C. J., Gunby, R. H., Coluccia, A. M. L., Sottocornola, R., Cimbro, B., Scapozza, L., Donella‐Deana, A., Pinna, L. A., & Gambacorti-Passerini, C. B. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m706067200 · Cited by 84
Martinsson, T., Eriksson, T., Abrahamsson, J., Carén, H., Hansson, M., Kogner, P., Kamaraj, S., Schönherr, C., Weinmar, J., Ruuth, K., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-2366 · Cited by 84
Self-citationp130Cas mediates the transforming properties of the anaplastic lymphoma kinase
Ambrogio, C., Voena, C., Manazza, A. D., Piva, R., Riera, L., Barberis, L., Costa, C., Tarone, G., Defilippi, P., Hirsch, E., et al. (2005) · Blood · doi:10.1182/blood-2005-03-1204 · Cited by 84
Yao, S., Cheng, M. M., Zhang, Q., Wasik, M. A., Kelsh, R. N., & Winkler, C. (2013) · PLoS ONE · doi:10.1371/journal.pone.0063757 · Cited by 79
Overexpression of NPM–ALK induces different types of malignant lymphomas in IL-9 transgenic mice
de Lange, K., Uckert, W., Blankenstein, T. J. F., Nadrowitz, R., Bittner, C., Renauld, J., Snick, J. V., Feller, A. C., & Merz, H. (2003) · Oncogene · doi:10.1038/sj.onc.1206076 · Cited by 74
Stute, C., Schimmelpfeng, K., Renkawitz‐Pohl, R., Palmer, R. H., & Holz, A. (2004) · Development · doi:10.1242/dev.00972 · Cited by 73
Self-citationAntibody targeting of anaplastic lymphoma kinase induces cytotoxicity of human neuroblastoma
Carpenter, E. L., Haglund, E. A., Mace, E. M., Deng, D., Martínez, D., Wood, A., Chow, A. K., Weiser, D. A., Belcastro, L. T., Winter, C. L., et al. (2012) · Oncogene · doi:10.1038/onc.2011.647 · Cited by 73
Colomba, A., Courilleau, D., Ramel, D., Billadeau, D. D., Espinos, E., Delsol, G., Payrastre, B., & Gaits‐Iacovoni, F. (2007) · Oncogene · doi:10.1038/sj.onc.1210921 · Cited by 71
Rohrbough, J. C., & Broadie, K. S. (2010) · Development · doi:10.1242/dev.047878 · Cited by 71
Turner, S. D., Tooze, R. M., MacLennan, K., & Alexander, D. R. (2003) · Oncogene · doi:10.1038/sj.onc.1207048 · Cited by 69
HIP1–ALK, a Novel Fusion Protein Identified in Lung Adenocarcinoma
Hong, M. E., Kim, R. N., Song, J., Choi, S., Oh, E., Lira, M. E., Mao, M., Takeuchi, K., Han, J., Kim, J., et al. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000061 · Cited by 68
Cazes, A., Louis‐Brennetot, C., Mazot, P., Dingli, F., Lombard, B., Boeva, V., Daveau, R., Cappo, J., Combaret, V., Schleiermacher, G., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-1242 · Cited by 67
Zhang, H., Pao, L. I., Zhou, A. J., Brace, A. D., Halenbeck, R., Hsu, A. W., Bray, T. L., Hestir, K., Bosch, E., Lee, E., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1412009111 · Cited by 67
McDonnell, S. R. P., Hwang, S. R., Rolland, D. C. M., Murga‐Zamalloa, C., Basrur, V., Conlon, K. P., Fermin, D., Wolfe, T., Raskind, A. B., Ruan, C., et al. (2013) · Blood · doi:10.1182/blood-2013-01-482026 · Cited by 66
Crizotinib — Latest Champion in the Cancer Wars?
Hallberg, B., & Palmer, R. H. (2010) · New England Journal of Medicine · doi:10.1056/nejme1010404 · Cited by 66
Self-citationMazot, P., Cazes, A., Boutterin, M., Figueiredo, A. L., Raynal, V., Combaret, V., Hallberg, B., Palmer, R. H., Delattre, O., Janoueix‐Lerosey, I., et al. (2011) · Oncogene · doi:10.1038/onc.2010.595 · Cited by 65
Self-citationAmbrogio, C., Voena, C., Manazza, A. D., Martinengo, C., Costa, C., Kirchhausen, T. L., Hirsch, E., Inghirami, G., & Chiarle, R. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-2568 · Cited by 65
Donella‐Deana, A., Marin, O., Cesaro, L., Gunby, R. H., Ferrarese, A., Coluccia, A. M. L., Tartari, C. J., Mologni, L., Scapozza, L., Gambacorti-Passerini, C. B., et al. (2005) · Biochemistry · doi:10.1021/bi0472954 · Cited by 64
Efficacy of a Cancer Vaccine against ALK -Rearranged Lung Tumors
Voena, C., Menotti, M., Mastini, C., Giacomo, F. D., Longo, D. L., Castella, B., Merlo, M. E. B., Ambrogio, C., Wang, Q., Minero, V. G., et al. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0089 · Cited by 64
Chen, Z., Akbay, E. A., Mikse, O. R., Tupper, T., Cheng, K. A., Wang, Y., Tan, X., Altabef, A. B., Woo, S.-A., Chen, L., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1733 · Cited by 61
Toyokawa, G., Inamasu, E., Shimamatsu, S., Yoshida, T., Nosaki, K., Hirai, F., Yamaguchi, M., Seto, T., Takenoyama, M., & Ichinose, Y. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000509 · Cited by 61
Aberrant activation of ALK kinase by a novel truncated form ALK protein in neuroblastoma
Okubo, J., Takita, J., Chen, Y., Oki, K., Nishimura, R., Kato, M., Sanada, M., Hiwatari, M., Hayashi, Y., Igarashi, T., et al. (2012) · Oncogene · doi:10.1038/onc.2011.616 · Cited by 60
Chand, D., Yamazaki, Y., Ruuth, K., Schönherr, C., Martinsson, T., Kogner, P., Attiyeh, E. F., Maris, J. M., Morozova, O., Marra, M. A., et al. (2012) · Disease Models & Mechanisms · doi:10.1242/dmm.010348 · Cited by 60
Self-citationMori, M., Ueno, Y., Konagai, S., Fushiki, H., Shimada, I., Kondoh, Y., Saito, R., Mori, K., Shindou, N., Soga, T., et al. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0395 · Cited by 60
Zebrafish Leucocyte tyrosine kinase controls iridophore establishment, proliferation and survival
Fadeev, A., Krauss, J., Singh, A. P., & Nüsslein‐Volhard, C. (2016) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12454 · Cited by 58
MicroRNA 96 Is a Post-Transcriptional Suppressor of Anaplastic Lymphoma Kinase Expression
Vishwamitra, D., Li, Y., Wilson, D., Manshouri, R., Curry, C. V., Shi, B., Tang, X., Sheehan, A. M., Wistuba, I. I., Shi, P., et al. (2012) · American Journal Of Pathology · doi:10.1016/j.ajpath.2012.01.008 · Cited by 58
Ouyang, T., Bai, R.-Y., Bassermann, F. C., von Klitzing, C., Klümpen, S., Miething, C., Morris, S. W., Peschel, C., & Duyster, J. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m300883200 · Cited by 57
Fransson, S. M., Hansson, M., Ruuth, K., Djos, A., Berbegall, A. P., Javanmardi, N., Abrahamsson, J., Palmer, R. H., Noguera, R., Hallberg, B., et al. (2014) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22223 · Cited by 53
Self-citationTargeted Disruption of ALK Reveals a Potential Role in Hypogonadotropic Hypogonadism
Witek, B., Wakil, A. E., Nord, C., Ahlgren, U., Eriksson, M., Vernersson-Lindahl, E., Helland, Å., Alexeyev, O. A., Hallberg, B., & Palmer, R. H. (2015) · PLoS ONE · doi:10.1371/journal.pone.0123542 · Cited by 50
Self-citationKamaraj, S., Hochgräfe, F., Wu, J., Umapathy, G., Schönherr, C., Ruuth, K., Chand, D., Witek, B., Fuchs, J. R., Li, P., et al. (2013) · FEBS Journal · doi:10.1111/febs.12453 · Cited by 48
Self-citationPearson, J. D., Lee, J. K. H., Bacani, J. T. C., Lai, R. L., & Ingham, R. J. (2011) · PubMed · Cited by 41
The Neuroblastoma ALK(I1250T) Mutation Is a Kinase-Dead RTK In Vitro and In Vivo
Schönherr, C., Ruuth, K., Eriksson, T., Yamazaki, Y., Ottmann, C., Combaret, V., Vigny, M., Kamaraj, S., Palmer, R. H., & Hallberg, B. (2011) · Translational Oncology · doi:10.1593/tlo.11139 · Cited by 38
Self-citationOncogenic kinase NPM/ALK induces expression of HIF1α mRNA
Marzec, M., Liu, X., Wong, W. J., Yang, Y., Pasha, T. L., Kantekure, K., Zhang, P., Woetmann, A., Cheng, M. M., Ødum, N., et al. (2010) · Oncogene · doi:10.1038/onc.2010.505 · Cited by 37
Kodityal, S., Elvin, J. A., Squillace, R. M., Agarwal, N., Miller, V. A., Ali, S. M., Klempner, S. J., & Ou, S. I. (2015) · Lung Cancer · doi:10.1016/j.lungcan.2015.11.023 · Cited by 31
Dupuis-Coronas, S., Lagarrigue, F., Ramel, D., Chicanne, G., Saland, E., Gaits‐Iacovoni, F., Payrastre, B., & Tronchère, H. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.227512 · Cited by 28
Ueda, T., Nakata, Y., Yamasaki, N., Oda, H., Sentani, K., Kanai, A., Onishi, N., Ikeda, K., Sera, Y., Honda, Z.-I., et al. (2016) · Oncogene · doi:10.1038/onc.2015.519 · Cited by 23
Wang, P., Wu, F., Zhang, J., McMullen, T. P. W., Young, L. C., Ingham, R. J., Li, L., & Lai, R. L. (2010) · Carcinogenesis · doi:10.1093/carcin/bgq229 · Cited by 15
Cited by
Bensch, F., van der Veen, E. L., Lub-de Hooge, M. N., Jorritsma-Smit, A., Boellaard, R., Kok, I. C., Oosting, S. F., Schröder, C. P., Hiltermann, T. J. N., van der Wekken, A. J., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0255-8 · Cited by 732
Loree, J. M., Pereira, A. A. L., Lam, M., Willauer, A. N., Raghav, K., Dasari, A., Morris, V. K., Advani, S., Menter, D. G., Eng, C., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2484 · Cited by 316
Tumor mutational burden quantification from targeted gene panels: major advancements and challenges
Fancello, L., Gandini, S., Pelicci, P. G., & Mazzarella, L. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0647-4 · Cited by 310
Immuno-Oncology: Emerging Targets and Combination Therapies
Marshall, H. T., & Djamgoz, M. B. A. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00315 · Cited by 301
Neuroblastoma—A Neural Crest Derived Embryonal Malignancy
Johnsen, J. I., Dyberg, C., & Wickström, M. (2019) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2019.00009 · Cited by 277
Metadata
- Authors
- Hallberg, B., & Palmer, R. H.
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2016-09
- Volume
- 27
- Pages
- iii4-iii15
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W2515048758
- Cited by
- 377
- References
- 134
- FWCI
- 21.45
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.